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Background: There is only limited experience with wearable cardioverter-defibrillators (WCD) in pediatric patients.
We report on the successful application of a WCD in an adolescent patient with hypertrophic cardiomyopathy and
myocardial bridging.
Case presentation: A 15-year-old girl presented with a history of recurrent syncope, dyspnea, and vertigo with
exercise. Diagnostic work-up revealed non-obstructive hypertrophic cardiomyopathy and signs of myocardial
ischemia with exercise. Given this high-risk constellation, the patient was scheduled for prophylactic implantation of
an implantable cardioverter-defibrillator (ICD). One month after initial presentation and days prior to the planned
ICD implantation, the patient collapsed during an episode of sustained ventricular tachycardia (VT) while running.
VT was terminated by WCD shock delivery. Following this event, computerized tomography scan revealed
myocardial bridging of the left anterior descending coronary artery causing a 90% stenosis in systole. After coronary
surgery, life threatening arrhythmias have not recurred, but due to progressive heart failure, the patient underwent
successful heart transplantation after 2 years.
Conclusions: The reported case highlights the importance and applicability of WCDs and the potentially malign
nature of myocardial bridging in pediatric high-risk patients.
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Implantable cardioverter-defibrillators (ICDs) represent
a well established treatment option for patients at high
risk for sudden cardiac death (SCD). Data supporting
the efficacy in preventing SCD by ICDs have been shown
by several randomized-controlled studies [1–4]. How-
ever, there are clinical scenarios where the use of an
ICD is temporarily not feasible or implantation criteria
are not yet met. The wearable cardioverter-defibrillator
(WCD) is a temporary non-invasive device used for pre-
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Fig. 1 Sudden onset polymorphic ventricular tachycardia. After 30 s the LifeVest delivered an appropriate shock, converting ventricular
tachycardia into sinus rhythm
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when implantation criteria for an ICD are not met [5].
Data on the use of WCDs as bridging to ICD implant-
ation in high-risk pediatric patients with hypertrophic
cardiomyopathy are limited. We report on the use of a
WCD in a 15-year-old girl suffering from ventricular
tachycardia (VT) due to myocardial bridging and non-
obstructive hypertrophic cardiomyopathy.
Case presentation
A 15-year-old girl presented a history of recurrent syn-
cope, dyspnea and dizziness. Echocardiography revealed
a non-obstructive hypertrophic cardiomyopathy with a
septal thickness of 25 mm (z-score + 17) and impaired
diastolic function. Repeated Holter ECG monitoringrevealed no life threatening arrhythmias. The patient
was started on beta-blockers (metoprolol). Risk stratifi-
cation was performed according to the 2014 ESC guide-
lines [6] estimating a 5-year risk for sudden cardiac
death (SCD) of 7%, indicating that an ICD should be
considered. Throughout the process of finalizing diag-
nostic work-up and decision making, we instructed the
girl for meticulous use of a wearable cardioverter-
defibrillator (LifeVest, ZOLL, Pittsburgh, Pennsylvania,
USA). Further work-up included genetic testing, reveal-
ing a TNNC-1 gene mutation known to be related to
hypertrophic cardiomyopathy [7]. However, family his-
tory was unremarkable in regard to sudden cardiac death
or cardiomyopathy. Exercise testing (bicycle ergometer)
resulted in angina symptoms and ST-segment
Fig. 2 Sinus tachycardia (160 bpm) with ST-segment depression consistent with myocardial ischemia, which was then followed by sudden onset
polymorphic ventricular tachycardia
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imum performance of 1.2W/kg. Symptoms resolved
quickly after discontinuing exercise. Magnetic resonance
imaging (MRI) and late gadolinium enhancement re-
vealed areas of lower perfusion and fibrosis. The patient
was scheduled for implantation of an ICD system given
her high-risk constellation. Five days prior to the sched-
uled ICD implantation, after wearing the WCD for 6
weeks, the patient was admitted after experiencing an-
other syncope with successful termination of a sustained
VT by the WCD. During that episode she was running a
very short distance to catch the school bus but then
collapsed inside the crowded vehicle. After shock deliv-
ery by the WCD she recovered very quickly and was ad-
mitted to the hospital completely uncompromised. The
ECG documented by LifeVest revealed severe ischemic
changes right before initiation of ventricular tachycardia.
Figure 1 shows VT and shock delivery by the WCD on
the ECG tracing obtained by LifeVest. The ischemic
changes (Fig. 2) prompted a computerized tomography
(CT) scan of the coronary arteries. Subsequent coronary
angiography revealed myocardial bridging of the left
anterior descending coronary artery (LAD) causing a
90% stenosis in systole (Fig. 3 shows a 3D reconstruction
from the CT scan). The patient underwent surgical
unroofing of the LAD and a left internal mammarianbypass proximal to the bridged LAD was performed.
Due to sustained VT, low cardiac output and low perfu-
sion of the distal portion of LAD, a venous bypass dis-
tally to the bridged artery was performed during the
same session. Postoperatively she needed 3 days of
mechanical cardiac support and recovered slowly. Fi-
nally, an ICD was implanted. Following the single event
of VT, life threatening arrhythmias have not recurred.
Due to progressive restrictive heart failure and increas-
ing severe angina symptoms following occlusion of the
left mammarian artery bypass, she successfully under-
went heart transplantation 2 years after her first event.
Discussion and conclusions
The American Heart Association released guidelines on
the indications of WCDs in 2016 [8]. WCD use was ap-
proved by the FDA in 2015 for children with a minimum
weight of 42 pounds and a minimum chest circumfer-
ence of 26 in., resembling an 8 year-old. Currently, Life-
Vest (ZOLL, Pittsburgh, Pennsylvania, USA) is the only
WCD approved for clinical use. It has built-in electrodes
for rhythm sensing, and pads to deliver a shock if neces-
sary [9, 10]. In certain situations, when criteria for an
implantable ICD are not entirely met and/or a transient
risk for SCD exists, the WCD system represents a non-
invasive but potentially life-saving treatment option.
Fig. 3 Three dimensional reconstruction of the computerized
tomography scan and angiography depicting myocardial bridging of
the left anterior descending coronary artery
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where criteria for ICD implantation are often not ful-
filled and/or improvements of the condition is expected.
Data on the use of WCDs in pediatric patients still re-
main scarce and additional evidence on the use of
WCDs in pediatric patients is warranted. In addition,
risk stratification for SCD was established in the adult
population [11], while risk stratification for SCD in the
younger pediatric population is less well validated. Thus,
WCD indications might be applied less rigidly in chil-
dren below 16 years of age when compared to adults. By
applying the above mentioned adult risk stratification
[11] to our adolescent patient, we found our patient to
have an indication for an ICD and chose the WCD sys-
tem as a protective bridge to ICD implantation.
Acceptance of treatment, by patients and parents, is an
important factor and is probably higher for WCDs than
for ICDs or subcutaneous cardioverter defibrillators
(SICDs). Furthermore, ICDs show relatively high rates of
complications in pediatric patients, most commonly re-
lated to lead problems which potentially have significant
impact on the patient’s quality of life [12, 13]. Accept-
ance of treatment and comfort when waring the WCD
system seems of outmost importance considering that
the longest possible wearing time per day must be
achieved in order to obtain maximum efficiency. WCD
systems seem to be highly effective in terminating VT/
VF in pediatric patients and inappropriate shock deliver-
ies are infrequently observed [5].
Myocardial bridging is considered a benign variation
of coronary development present in about 25% of the
population. However, it may cause severe cardiac condi-
tions, especially with underlying heart disease [14]. InHCM, signs of myocardial ischemia should trigger evalu-
ation for myocardial bridging as a potentially treatable
cause, and due to the risk of SCD, WCD use should be
considered as a transient treatment option until surgical
relief is performed. In our case, ischemic findings on the
WCD tracing prior to shock delivery helped establish
the diagnosis of myocardial bridging.
In conclusion, this case reports on the use of WCD as
a bridge to ICD in a high-risk pediatric patient with
HCM and myocardial bridging. The WCD allowed for
primary protection from SCD while awaiting further
diagnostic work-up.
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